Cidara Therapeutics, Inc. (CDTX) financial statements (2022 and earlier)

Company profile

Business Address 6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments59,68035,91250,26874,56275,314104,619107,514
Cash and cash equivalents59,68035,91250,26874,56260,81385,36762,562
Short-term investments    14,50119,25244,952
Restricted cash and investments2,5937,03710,000    
Receivables5,35611,175  321  
Other undisclosed current assets4,0693,0675,5462,5672,035779704
Total current assets:71,69857,19165,81477,12977,670105,398108,218
Noncurrent Assets
Operating lease, right-of-use asset2,2878681,632
Property, plant and equipment2563424297121,0441,3741,684
Other noncurrent assets1,0842,0231,1011,27132119072
Total noncurrent assets:3,6273,2333,1621,9831,3651,5641,756
TOTAL ASSETS:75,32560,42468,97679,11279,035106,962109,974
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,35816,7379,6139,5539,4188,9095,974
Accounts payable1,3014,5681,8872,8462,5902,9093,095
Accrued liabilities10,1987,9594,0683,8834,2573,3381,415
Employee-related liabilities4,8594,2103,6582,8242,5712,6621,464
Debt2,5917,02310,7839,9282,667  
Derivative instruments and hedges, liabilities   411   
Other undisclosed current liabilities15,06814,8049,803    
Total current liabilities:34,01738,56430,19919,89212,0858,9095,974
Noncurrent Liabilities
Long-term debt and lease obligation1,322 942    
Operating lease, liability1,322 942
Liabilities, other than long-term debt   81 8088
Other liabilities   81 8088
Other undisclosed noncurrent liabilities17,09111,145  7,2069,794 
Total noncurrent liabilities:19,73511,145942817,2069,87488
Total liabilities:53,75249,70931,14119,97319,29118,7836,062
Stockholders' equity
Stockholders' equity attributable to parent21,57310,71537,83559,13959,74488,179103,912
Common stock7433221
Additional paid in capital398,733345,411297,659277,871209,140181,840149,416
Accumulated other comprehensive loss    (8)(1)(8)
Accumulated deficit(377,167)(334,700)(259,827)(218,735)(149,390)(93,662)(45,497)
Total stockholders' equity:21,57310,71537,83559,13959,74488,179103,912
TOTAL LIABILITIES AND EQUITY:75,32560,42468,97679,11279,035106,962109,974

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(91,827)(83,916)(62,639)(63,285)(55,721)(48,436)(32,313)
Other undisclosed operating income49,57212,06720,915    
Operating loss:(42,255)(71,849)(41,724)(63,285)(55,721)(48,436)(32,313)
Nonoperating income (expense)(212)(262)6324,269(7)271120
Other nonoperating income (expense)(212)(262)6324,269(7)271 
Interest and debt expense(12)(5)(8)(13)(18)(5)(22)
Net loss:(42,479)(72,116)(41,100)(59,029)(55,746)(48,170)(32,215)
Other undisclosed net income attributable to parent12581318522
Net loss attributable to parent:(42,467)(72,111)(41,092)(59,016)(55,728)(48,165)(32,193)
Preferred stock dividends and other adjustments (2,762) (10,329)   
Net loss available to common stockholders, diluted:(42,467)(74,873)(41,092)(69,345)(55,728)(48,165)(32,193)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(42,479)(72,116)(41,100)(59,029)(55,746)(48,170)(32,215)
Comprehensive loss:(42,479)(72,116)(41,100)(59,029)(55,746)(48,170)(32,215)
Other undisclosed comprehensive income, net of tax, attributable to parent125821111214
Comprehensive loss, net of tax, attributable to parent:(42,467)(72,111)(41,092)(59,008)(55,735)(48,158)(32,201)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: